Our process is radically different and uses CHEMSAS – our proprietary drug discovery platform technology based upon a hybrid of machine learning technologies and proprietary algorithms. CHEMSAS utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. In other words, much of the discovery work is performed in computer simulations, which is very cost-effective in terms of identifying high probability drug candidates that we want to move forward with.
To make a long story short, CHEMSAS dramatically reduces the time and cost of the drug discovery process. Moreover, our largely computerized process has already identified a number of extremely promising drug candidate molecules.